Improving Scalability of PLGA-based Drug Products for Parenteral Administration

Overview:

This discussion will involve diving into aspects of parenteral formulations containing the biodegradable polymer, poly(lactic-co-glycolic acid) “PLGA”. You will leave this presentation with an understanding of how to properly scale PLGA based microparticles and in situ forming gel depots from lab to late-clinical phase. Many scalability factors will be discussed including manufacturing bottlenecks, particle generation techniques, sterility, and physical formulation aspects.

Key Learning Objectives:

• Scalability of current poly (lactic-co-glycolic acid) formulations to meet manufacturing demand for both microparticle and in situ forming gel depots.
• Manufacturing routes for in situ gel depots and how physical characteristics affect sterility options.
• Future trends in PLGA based parenteral products.

Who Should Attend:

• Formulation Scientists
• Research and Development (R&D) Scientists
• Clinical Trial Manufacturing Scientists and Operators
• Directors and Senior Directors of R&D
• Directors and Senior Directors of GMP Manufacturing

If you missed part I, check out "Improving Scalability of PLGA-Based Drug Products for Parenteral Administration" also presented by Matthew Owen.

Find Additional Formulation Offerings

Speaker:

Matthew Owen, Ph.D.

Matthew graduated with his BS in Chemistry from UC Berkeley, and following completion, he moved on to the UC Davis for his Ph.D. in Physical Chemistry. His research was focused on drug delivery, such as long-acting injectables and dry-powder inhalables. He is the author of numerous scientific publications and patents. He now works at Pace® Life Sciences, where he continues to develop complex formulations and analytical methodology for a wide range of applications.